• Home
  • Company
    • Management
    • Board of Directors
    • Advisory Board
  • Technology
    • Publications
  • Partnering
    • Product Pipeline
  • News
    • IN THE PRESS: Cloud Pharmaceuticals CSO Shahar Keinan in "The Scientist"
    • Cloud Pharmaceuticals to Present AI-Based Drug Design at Conferences in May
    • Cloud Pharmaceuticals Wins U.S.-China Health Summit
    • Cloud Pharmaceuticals Selected Finalist in U.S.-China Health Summit
    • Cloud Pharmaceuticals forms Drug Design Collaboration with GSK
    • Cloud Pharmaceuticals CEO to Speak at Artificial Intelligence in Drug Development Congress 27-28 September 2017, London, UK
    • Cloud Pharmaceuticals CEO and CSO to Speak at AI Pharma Innovation
    • Cloud Pharmaceuticals CEO to Speak at the AI in Pharma Summit October17, 2017 in Boston.
    • Cloud Pharmaceuticals CEO and CSO to Speak at AI Pharma Innovation
    • Undruggable? Not to Cloud Pharmaceuticals
    • Cloud Pharmaceuticals Announces Design of Active Pro-Drug for Treatment of Crohn's Disease and Ulcerative Colitis
    • Cloud Pharmaceuticals COO to Discuss Digital Tools for Drug Discovery and Development at the 2016 BIO International Convention
    • Cloud Pharmaceuticals Appoints Neurological Disorder Expert Jeff Vaught to Its Advisory Board
    • Cloud Pharmaceuticals Strengthens Management Team with Appointment of Two C-Level Executives
  • Events
  • Contact
Cloud Pharmaceuticals
Connect with us:

Cloud in Print

"An Effective Way to Apply AI to the Design of New Drug Lead Compounds"
 Keinan, S.; Shipman, W. J.; and Addison, E.; Pharma IQ Clin. Disc. & Dev. (2019) June 11.
https://www.pharma-iq.com/pre-clinical-discovery-and-development/articles/an-effective-way-to-apply-ai-to-the-design-of-new-drug-lead-compounds

“Using Quantum Molecular Design & Cloud Computing to Improve the Accuracy & Success Probability of Drug Discovery”
Addison, E.; and Keinan, S.; Drug Dev. Delivery (2016) 16(2) 62-66.

https://drug-dev.com/cloud-computing-using-quantum-molecular-design-cloud-computing-to-improve-the-accuracy-success-probability-of-drug-discovery/

“Phospholipid-Based Prodrugs for Drug Targeting in Inflammatory Bowel Disease: Computational Optimization and in-Vitro Correlation”
Dahan, A.; Ben-Shabat, S.; Cohen, N.; Keinan, S.; Kurnikov, I.; Aponick, A.; and Zimmermann, E. M.; Curr. Top. Med. Chem. (2016) 16 2543-2548.

https://www.ingentaconnect.com/content/ben/ctmc/2016/00000016/00000023/art00005
 

“The Serpintine Solution”
Lucas, A.; Ambadapadi, S.; Mahon, B.; Viswanathan, K.; Chen, H.; Liu, L.; Dai, E.; Munuswami-Ramanujam, G.; Kwiecien, J. M.; Yaron, J. R.; Narute, P. S.; McKenna, R.; Keinan, S.; Reeves, W.; Brantly, M.; Pepine, C.; and McFadden, G.; J. Clin. Exp. Cardiolog. (2017) 8(1).

https://www.omicsonline.org/open-access/the-serpintine-solution-2155-9880-1000e150.php?aid=85215
 

“In Silico Prediction of Ligand Binding Energies in Multiple Therapeutic Targets and Diverse Ligand Chemotypes – A Case Study on BACE1, TYK2, HSP90 and PERK Proteins”
Hatcher-Frush, E.; Sekharan, S.; and Keinan, S.; J. Phys. Chem. B (2017) 121 8142-8148.
https://pubs.acs.org/doi/abs/10.1021/acs.jpcb.7b07224


“Computational modeling and in-vitro/in-silico correlation of phospholipid-based prodrugs for targeted drug delivery in inflammatory bowel disease”
Dahan, A.; Markovic, M.; Keinan, S.; Kurnikov, I.; Aponick, A.; Zimmermann, E. M.; and Ben-Shabat, S.; J. Comp. Aided Mol. Des. (2017) 31 1021–1028 

https://link.springer.com/article/10.1007%2Fs10822-017-0079-5


“Crystal Structure of Serp-1, a Myxomavirus-derived Immune Modulating Serpin; Structural Design of Serpin Reactive Center Loop (RCL) Peptides with Improved Therapeutic Function”
Mahon, B. P.; Ambadapadi, S.; Yaron, J.; Lomelino, C. L.; Pinard, M. A.; Keinan, S.; Kurnikov, I.; Macaulay, C.; Reeves, W.; McFadden, G.; Tibbetts, S.; McKenna, R.; and Lucas, A. R.; Biochemistry  (2018) 57 1096-1107
https://pubs.acs.org/doi/10.1021/acs.biochem.7b01171
 

“Activation of the ß-common receptor by erythropoietin impairs acetylcholine mediated endothelium-dependent vasodilation in mouse mesenteric arterioles”
Kilar, C. R.; Diao, Y.P.; Sautina, L.; Sekharan, S.; Keinan, S.; Conrad, K.P.; Mohandas, R.; and Segal, M. S.; Physiol Rep. (2018) 6(12) e13751
https://physoc.onlinelibrary.wiley.com/doi/abs/10.14814/phy2.13751

 
“Computational Design and Experimental Characterization of a Novel ß-Common Receptor Inhibitory Peptide” 
Kilar, C. R.; Sekharan, S.;  Sautina, L.; Diao, Y.P.; Keinan, S.; Shen, Y.; Bungert, J.; Mohandas, R.; and Segal, M. S.; Peptides (2018) 104 1-6
https://www.sciencedirect.com/science/article/abs/pii/S019697811830069X

​
“Leveraging cloud computing for In-Silico drug design”
Keinan, S.; Hatcher-Frush, E.; and Shipman, W. J.; IEEE Trans. Comp. Sci. Eng. 10 July 2018

https://ieeexplore.ieee.org/abstract/document/8409367/​

"Prospects and Challenges of Phospholipid-Based Prodrugs"
​Milica Markovic, Shimon Ben-Shabat, Shahar Keinan, Aaron Aponick, Ellen M. Zimmermann and Arik Dahan; ​Pharmaceutics2018,10, 210; doi:10.3390/pharmaceutics10040210 November 2018
https://www.researchgate.net/publication/328683997_Prospects_and_Challenges_of_Phospholipid-Based_Prodrugs
HOME | COMPANY | TECHNOLOGY | PARTNERING | NEWS | EVENTS | CONTACT

CONTACT US:

Cloud Pharmaceuticals, Inc.

Office: 800 Park Offices Dr., RTP, NC 27709
Mail: PO Box 110081, RTP, NC 27709
Phone: 1.910.398.1200
e-mail: info@cloudpharmaceuticals.com
CONNECT WITH US:


SUBSCRIBE:

Join our contact list to receive news and announcements in your inbox:

Join Now
© 2014 - 2019 Cloud Pharmaceuticals, Inc. | Terms and Conditions of access to www.cloudpharmaceuticals.com